🇺🇸 FDA
Pipeline program

Human amniotic-derived mesenchymal stem cells

HOPE-CAMSC

Phase 1 mab active

Quick answer

Human amniotic-derived mesenchymal stem cells for Chronic Kidney Diseases is a Phase 1 program (mab) at First Tracks Biotherapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
First Tracks Biotherapeutics
Indication
Chronic Kidney Diseases
Phase
Phase 1
Modality
mab
Status
active

Clinical trials